Knoa Pharma LLC v. Accord Healthcare, Inc.

Knoa Pharma, formerly Purdue Pharmaceuticals L.P., owns the ’908 patent, which is directed to tamper-resistant extended-release opioid dosage forms. Purdue developed the claimed technology in response to abuse of the original OxyContin product, which could be crushed and snorted or mixed with liquid and injected to deliver oxycodone more rapidly than intended.... By: Robins Kaplan LLP